Literature DB >> 1748569

[ENT antibiotic therapy: therapeutic guidelines. Part I].

P Federspil1.   

Abstract

We discuss the variety of ear, nose and throat infections and then define the criteria for the choice of an adequate antibiotic. The importance of "supercalculated" therapy based on the results of Gram's stain is stressed, as it can save patients from over-treatment and adverse side-effects. Indications for Gram's stain in ENT as well as the value of the characteristics of the pus produced by different pathogens are described. The severity of the infection determines the choice between parenteral or oral therapy. The importance of the decision taken on the 1st and 3rd day of a severe infection is emphasised. Therapeutic principles in ENT infections are shown by grouping different infections with a similar spectrum of pathogens; also the indications for antibiotic therapy are outlined. Finally the priority of antibiotic treatment in some surgical infections is mentioned, and the peri-operative prophylaxis and treatment are described as well as the guidelines for treatment of infectious post-operative complications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748569

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

1.  [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

2.  DRUGS system enhancing adherence of Chinese surgeons to antibiotic use guidelines during perioperative period.

Authors:  Zhifu Yang; Peixi Zhao; Jingwen Wang; Liping Tong; Jinyi Cao; Yun Tian; Zhanpeng Yao; Jingbo Wang; Yanrong Zhu; Yanyan Jia; Aidong Wen
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

Review 3.  [Antibiotic therapy in otorhinolaryngology].

Authors:  P Federspil; P A Federspil
Journal:  HNO       Date:  2005-01       Impact factor: 1.284

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.